Navigation Links
Boston Scientific Announces Schedule for EuroPcr 2007

Company to release broad range of clinical data on leading drug-eluting stent portfolio

NATICK, Mass., May 15, 2007 /PRNewswire-FirstCall/ -- Boston Scientific Corporation today announced the schedule of the Company's major events and press announcements at the annual Paris Course on Revascularization (EuroPCR), which will runs from May 22 to 25 in Barcelona, Spain.

"We will be announcing new data from several of our clinical trials and registries, adding to the knowledge base for treating coronary artery disease," said Paul LaViolette, Chief Operating Officer of Boston Scientific. "Pooled data from our ARRIVE registries will shed light on key predictors for stent thrombosis in real-world DES use. Additional data will provide insight into the performance of our market-leading TAXUS(R) paclitaxel-eluting stent systems as well as our new everolimus-based PROMUS(TM) (XIENCE(TM) V) stent system, reinforcing Boston Scientific's role as the only company offering two distinct drug-eluting stent platforms."

    Schedule of Events (all times are local Barcelona)


    Tuesday, May 22


    * The Great Debate on DES.  The Company will host a symposium entitled

      "The Great Debate on Coronary Drug-Eluting Stents," chaired by Jean

      Marco, M.D., and Steven Nissen, M.D., from 1:30 - 3:15 p.m. in Room 1 of

      The Centre de Convencions Internacional de Barcelona.  Experts will

      debate and answer questions from interventional cardiologists related to

      coronary drug-eluting stent usage in daily practice.


    * TAXUS VI four-year data.  At 5:01 p.m., Professor Eberhard Grube, M.D.,

      will present four-year results from the TAXUS VI trial in a late-

      breaking session.  This randomized, double-blind trial is designed to

      assess the safety and efficacy of a moderate-release (non-

      commercialized) formulation paclitaxel-eluting stent versus a bare metal

      stent control group.  Data will be presented on examined s
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Boston Life Sciences, Inc. Announces Presentation of Cethrin Phase I/IIa 6-Month Results at 75th Annual Meeting of the American Association of Neurological Surgeons
2. Bio-Matrix Scientifics Dr. ONeill Sees University of Pittsburghs Published Study on Culture Blood-Forming Stem Cells from Human Fat Tissue as Supporting Near Term Benefits of Banking Adipose (Fat) Derived Stem Cells
3. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
4. VIVUS Announces Abstract Published at American Diabetes Association Scientific Sessions
5. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Mechanism of Action and Clinical Activity of Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American Diabetes Association 67th Scientific Sessions in Chicago, Illinois
6. MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating MacroVascular Outcomes Presented at the American Diabetes Association 67th Scientific Sessions
7. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
8. Genaera to Present Preclinical Data on Trodusquemine for the Treatment of Obesity at the American Diabetes Association 67th Scientific Sessions
9. VeroScience Late-Breaking Abstract on Cycloset (A Quick Release Formulation of Bromocriptine Mesylate) Accepted for Poster Presentation at American Diabetes Association 67th Scientific Sessions
10. Inspire Announces Presentations at Two European Scientific Conferences
11. HepaLife Announces Scientific Presentation of PBS-1 Cell Line at International Influenza Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Boston Scientific Announces Schedule for EuroPcr
(Date:10/22/2014)... and AUSTIN, Texas , ... PureMHC LLC today announced they have entered into ... antibody-based immunotherapies designed to target cancers. ... peptides displayed on the surfaces of tumor cells ... targets (PTTs), derived from proteins that play a ...
(Date:10/22/2014)... -- Recently published clinical studies of Stretta for gastroesophageal reflux ... evidence. This data has led to significantly expanded insurance ... sufferers of refractory GERD. The substantial ... as a safe and effective GERD treatment has driven ... nearly 50 million Americans. The new clinical studies include; ...
(Date:10/20/2014)... MOUNTAIN VIEW, Calif. , Oct. 20, 2014 /PRNewswire/ ... field of interventional pulmonology, today announced completion of enrollment ... schedule.  The RENEW Clinical Study is the FDA-approved IDE ... treatment for severe emphysema. It was anticipated ... US in February 2013, would take until the end ...
Breaking Medicine Technology:Biotech Companies To Co-Discover And Co-Develop Antibodies Targeting Novel Phosphopeptide Tumor Targets 2Recent Clinical Study Data Confirms Efficacy of Stretta Therapy - Spurs Additional Insurance Coverage and Financing Round 2PneumRx Completes RENEW Pivotal Trial Enrollment 2PneumRx Completes RENEW Pivotal Trial Enrollment 3
... Inc. (Nasdaq: MSON ), a developer of minimally invasive ... the ablation of tumors and worldwide for other acute health ... year ended June 30, 2009. , The Company also reported ... payment of $3.5 million was received on April 7, 2009 ...
... , SAN MATEO, Calif., Oct. 1 Corthera Inc. ... (FDA) has granted Fast Track designation to relaxin, the ... failure (AHF). The Fast Track program facilitates the development ... treat serious or life-threatening conditions and that demonstrate the ...
Cached Medicine Technology:Misonix Reports Fourth Quarter and Fiscal Year 2009 Financial Results 2Misonix Reports Fourth Quarter and Fiscal Year 2009 Financial Results 3Misonix Reports Fourth Quarter and Fiscal Year 2009 Financial Results 4Misonix Reports Fourth Quarter and Fiscal Year 2009 Financial Results 5Misonix Reports Fourth Quarter and Fiscal Year 2009 Financial Results 6Misonix Reports Fourth Quarter and Fiscal Year 2009 Financial Results 7Misonix Reports Fourth Quarter and Fiscal Year 2009 Financial Results 8Misonix Reports Fourth Quarter and Fiscal Year 2009 Financial Results 9Misonix Reports Fourth Quarter and Fiscal Year 2009 Financial Results 10Corthera's Relaxin Receives FDA Fast Track Designation for the Treatment of Acute Heart Failure 2Corthera's Relaxin Receives FDA Fast Track Designation for the Treatment of Acute Heart Failure 3
(Date:10/22/2014)... Hay House is pleased to announce the official ... Life (Paperback; $10.82) written by the highly esteemed Tommy Rosen, ... book is meant to help readers of all kinds end ... , Recovery 2.0 is not the average self-help book, or ... guide for what comes next. For many, Alcoholics ...
(Date:10/22/2014)... Healthcare professionals who are looking for ... home or on-the-go via laptops, tablets or mobile ... premium Seminar-on-Demand CE courses. The new courses add ... hours of CE course offerings, allowing therapy ... such a diverse library, there’s something for everyone. ...
(Date:10/22/2014)... October 22, 2014 Richard Carlson, Managing ... industry leader with over 25 years experience. Mr. ... in the areas related to EDI, B2B Commerce, RFID ... an Editorial Advisory Board member for Pharmaceutical Commerce Magazine ... Blue Fin Group is a management and technology consulting ...
(Date:10/22/2014)... 21, 2014 (HealthDay News) -- Two sisters in high ... damage. Ilina and Medha Krishen use electronic stethoscopes, ... of trouble in breathing patterns or heartbeats. Ilina, ... Michigan, wanted to find a way to detect early ... Using an electronic stethoscope, Ilina recorded one breath cycle ...
(Date:10/22/2014)... HealthDay Reporter , MONDAY, Oct. ... officially tightened guidelines for health workers treating Ebola patients, now ... of a respirator at all times. The U.S. Centers ... rules after two Dallas nurses contracted Ebola while caring for ... national Thomas Eric Duncan. Nina Pham is currently being treated ...
Breaking Medicine News(10 mins):Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 2Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 3Health News:Top Provider of Continuing Education at Home Releases 20 New Online Courses 2Health News:Rich Carlson and Marc Duey to Hold Workshop at CBI’s Specialty Pharmacy and Distribution Networks Conference 2Health News:Teen Sisters Develop Ways to Measure Lung, Heart Damage 2Health News:CDC Tightens Rules on Caring for Ebola Patients 2Health News:CDC Tightens Rules on Caring for Ebola Patients 3
... sees telcos looking to find,viable solutions for improving public safety and network resiliency for all ... Americans, BOULDER, Colo., April 3, 2008 , WHO: ... Aztek Networks ( http://www.azteknetworks.net ), ... 20 years experience, Bruny has served as CEO of Aztek Networks, ...
... Rhytec, Inc. the pioneer,of plasma skin regeneration ... a novel thermal energy called plasma for reversing ... U.S. Food and Drug Administration (FDA),clearance to market ... is already cleared by the FDA for treating ...
... a,statement of William V. Corr, Executive Director, Campaign for ... broken Ohio,s,promise to protect its kids from tobacco by ... tobacco prevention program, run by the,Ohio Tobacco Prevention Foundation. ... carried out. More kids will become addicted to tobacco, ...
... Grubb &,Ellis Healthcare REIT, Inc. today announced the acquisition ... 3035, 3037, 3131, and 3133 Lakeland Hills Blvd., the ... buildings. Each,building has approximately 8,000 square feet of gross ... 1998 on approximately 4.64,acres, the buildings are cumulatively 90 ...
... Roy Blunt (Mo.) issued the following statement today after ... global AIDS initiative -,even though the president himself only ... the program couldn,t spend in 10,years what the majority ... more than one occasion that the president,s initiative on,fighting ...
... Disease Patients Rising, CHICAGO, April 2 ... disease and, according to the latest research,from Prevent ... number,is continuing to climb. With more than 130 ... million suffer from leading causes of vision loss ...
Cached Medicine News:Health News:Telecommunications Carriers Respond To Congress' Declaration of April as National 9-1-1 Education Month 2Health News:Telecommunications Carriers Respond To Congress' Declaration of April as National 9-1-1 Education Month 3Health News:Portrait(R) Plasma Receives Clearance from the FDA to Treat Acne Scars 2Health News:Portrait(R) Plasma Receives Clearance from the FDA to Treat Acne Scars 3Health News:Gov. Strickland, Legislative Leaders Break Promise to Protect Ohio's Kids from Tobacco 2Health News:Grubb & Ellis Healthcare REIT Acquires Vista Professional Center in Lakeland, Fla. 2Health News:Grubb & Ellis Healthcare REIT Acquires Vista Professional Center in Lakeland, Fla. 3Health News:Grubb & Ellis Healthcare REIT Acquires Vista Professional Center in Lakeland, Fla. 4Health News:Eye Disease Continuing to Increase Among Americans 2Health News:Eye Disease Continuing to Increase Among Americans 3
... Flexible excellence for patients and clinicians., ... Aestiva/5 anesthesia system, the Aestiva/5 MRI is ... systems with a fully functional, integrated ventilator. ... Gauss, 1.5 T active shielded magnet), the ...
... ventilator control panel is conveniently located on the ... angle whether standing or sitting. The ventilator control ... and numerics. The ventilator has CMV, PCV and ... available in two lengths facilitates both the placing ...
... The flexible, modular approach to meeting today's ... offers one of the best ergonomic solutions in ... to operate from any position. A revolving arm ... magazine and moveable patient cassette mean that there ...
... The Narkomed GS provides high quality ... interface. The proven technologies of the ... make the Narkomed GS user-friendly and ... high quality Narkomed GS is the ...
Medicine Products: